Dare Bioscience (DARE) EBITDA Margin (2016 - 2026)
Dare Bioscience's (DARE) quarterly EBITDA Margin came in at 143.72% in Q4 2025, down 860948.0% YoY from N/an in Q4 2024, and up 99.91% on a QoQ basis from 162340.76% in Q3 2025.
Dare Bioscience (DARE) EBITDA Margin (2016 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 6 years of EBITDA Margin data on file, last reported at 143.72% in Q4 2025.
- Quarterly EBITDA Margin fell 860948.0% year-over-year to 143.72% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1315.51% (up 23837669.0% YoY) and the FY2025 annual result came in at 1315.51%, up 23837669.0% from the prior year.
- EBITDA Margin advanced to 143.72% in Q4 2025, from 162340.76% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 18079.54% in Q2 2025 to a low of 162340.76% in Q3 2025.
- A 4-year average of 23986.31% and a median of 839.64% in 2023 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 5087866 bps in 2025, down 15111208 bps in 2025.
- Tracing DARE's EBITDA Margin over 4 years: stood at 3.84% in 2022, then slumped by 7543 bps to 286.05% in 2023, then jumped by 3060 bps to 8465.75% in 2024, then slumped by 102 bps to 143.72% in 2025.
- The last three EBITDA Margin figures came in at 143.72% (Q4 2025), 162340.76% (Q3 2025), and 18079.54% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Dare Bioscience | 12.39 Mn | -229,253.52 | -132,343.00 | -1,582.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,582.53% |
| Dec 31, 2025 | -143.72% |
| Sep 30, 2025 | -162,340.76% |
| Jun 30, 2025 | 18,079.54% |
| Mar 31, 2025 | -18,016.75% |
| Dec 31, 2024 | 8,465.75% |
| Sep 30, 2024 | -11,228.68% |
| Jun 30, 2024 | -32,799.12% |
| Mar 31, 2024 | -64,743.85% |
| Dec 31, 2023 | -286.05% |
| Sep 30, 2023 | -839.64% |
| Jun 30, 2022 | 3.84% |
| Jun 30, 2017 | -74.71% |
| Mar 31, 2017 | -19.17% |
| Dec 31, 2016 | -24.63% |